The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kireeva T.A.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Gumenetskaya Yu.V.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Biryukov V.A.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Obukhov A.A.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Makarova K.S.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Strikanova I.A.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Dzhabrailova S.O.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Lepilina O.G.

A.F. Tsyb Medical Radiology Research Center — Branch of the National Medical Research Radiology Center of the Ministry of Health of Russia

Ivanov S.A.

Tsyb Medical Radiology Research Center

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia;
Peoples’ Friendship University of Russia

Assessment of toxicity of elective pelvic lymph node irradiation in patients with high-risk prostate cancer

Authors:

Kireeva T.A., Gumenetskaya Yu.V., Biryukov V.A., Obukhov A.A., Makarova K.S., Strikanova I.A., Dzhabrailova S.O., Lepilina O.G., Ivanov S.A., Kaprin A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(2): 20‑24

DOI: 10.17116/onkolog20221102120

Views: 1054

Downloaded: 19

Download PDF (RU)
Contact the author
Table of contents

ASSESSMENT OF TOXICITY OF ELECTIVE PELVIC LYMPH NODE IRRADIATION IN PATIENTS WITH HIGH-RISK PROSTATE CANCER
ASSESSMENT OF TOXICITY OF ELECTIVE PELVIC LYMPH NODE IRRADIATION IN PATIENTS WITH HIGH-RISK PROSTATE CANCER

To cite this article:

Kireeva TA, Gumenetskaya YuV, Biryukov VA, et al. . Assessment of toxicity of elective pelvic lymph node irradiation in patients with high-risk prostate cancer. P.A. Herzen Journal of Oncology. 2022;11(2):20‑24. (In Russ.)
https://doi.org/10.17116/onkolog20221102120

Подписка 2025-2 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Close metadata
Recommended articles:
Resu­lts of the impact of personalized reha­bilitation on the quality of life of men after lapa­roscopic prostatectomy. P.A. Herzen Journal of Onco­logy. 2024;(4):22-28
Pote­ntial of specialized diet therapy in redu­cing toxic mani­festations in patients with meta­static castration-resistant prostate cancer with bone meta­stases during radionuclide therapy with radium chlo­ride [223Ra]. P.A. Herzen Journal of Onco­logy. 2024;(6):33-41
Predicting the effe­ctiveness of organ-preserving treatment of choroidal mela­noma using opti­cal cohe­rence tomo­graphy data. Russian Annals of Ophthalmology. 2024;(2-2):16-20
Patterns of CAF expression in tumors of the geni­tourinary system. Russian Journal of Archive of Pathology. 2024;(6):28-35

Combined modality radiotherapy increases the efficacy of treatment in patients with high-risk prostate cancer (PCa). The benefits of the elective inclusion of regional lymphatic collectors in the area of irradiation are unclear, since dose escalation, as well as an increase in the volume of irradiation, are associated with a high risk of treatment complications, which significantly affect the quality of patient live.

OBJECTIVE

To study the impact of elective pelvic lymph node irradiation on early results of the treatment and on quality of life in patients with high-risk prostate cancer.

MATERIAL AND METHODS

Combined modality radiotherapy with hormone therapy was performed in 60 patients with prostate cancer in MRRC, in the period from November, 2019 to January, 2021. The patients were randomized into 2 groups: with regional lymph node irradiation (n=32) and without irradiation (n=28). At the first stage of treatment, a course of conformal external beam radiotherapy (EBRT) was carried out in a total dose of 46 Gy. At the second stage of the treatment one session of high-dose-rate brachytherapy (192Ir) at a single dose of 15 Gy was performed.

RESULTS

Acute, grade 1 genitourinary (GU) toxicities occurred in 11 (34.4%) patients in the group with regional lymph node irradiation and in 8 (28.6%) patients in the group without additional irradiation (p .83). In group 2, one (3.6%) patient had GU toxicity of grade 2. Acute, grade 1 lower gastrointestinal (GI) toxicities were observed in 13 (40.6%) patients in the group with regional lymph node irradiation and in 3 (10.7%) patients in the group without additional irradiation (p=0.01).

CONCLUSIONS

The preliminary analysis showed an increase in the incidence of lower GI and GU toxicities in the group with elective regional lymph node irradiation.

Keywords:

prostate cancer
high risk
elective lymph node irradiation
dose escalation
radiation effects
combined modality radiotherapy
brachytherapy

Authors:

Kireeva T.A.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Gumenetskaya Yu.V.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Biryukov V.A.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Obukhov A.A.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Makarova K.S.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Strikanova I.A.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Dzhabrailova S.O.

A.F. Tsyb Medical Radiology Research Center — Branch National Medical Radiology Research Center of the Ministry of Health of Russia

Lepilina O.G.

A.F. Tsyb Medical Radiology Research Center — Branch of the National Medical Research Radiology Center of the Ministry of Health of Russia

Ivanov S.A.

Tsyb Medical Radiology Research Center

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia;
Peoples’ Friendship University of Russia

Received:

26.07.2021

Accepted:

25.10.2021

List of references:

  1. Kaprin AD, Starinskiy VV, Shakhzadova AO, eds. Malignant tumors in Russia in 2019 (morbidity and mortality). M.: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2020. (In Russ.).
  2. Kaprin AD, Starinskiy VV, Shakhzadova AO, eds. The state of oncological assistance to the population of Russia in 2019. M.: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2020. (In Russ.).
  3. Kaprin AD, Kostin AA, Tsybul’sky AD. Qulity of life patients with locally advanced prostate cancer as a creterion effectiveness of treatment. Problems of Oncology=Voprosy Onkologii. 2009;55(3):285-290. (In Russ.).
  4. Veliev EI, Okhrits VE, Obeid Akh. Prognostic factors of prostate cancer before and after radical prostatectomy. Cancer Urol. 2011;7(2):52-53. (In Russ.).
  5. Knipper S, Palumbo C, Pecoraro A, Rosiello G, Tian Z, Briganti A, Kevin CZ, Fred Saad F, Tilki D, Graefen M, Pierre I, Karakiewicz PI. Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9—10 at biopsy: A population-based analysis. Urol Oncol. 2020;38(3):79.e9-79.e14.  https://doi.org/10.1016/j.urolonc.2019.09.015
  6. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, et al. Clinical outcomes for patients with Gleason score 10 prostate adenocarcinoma: results from a multi-institutional consortium study. Int J Radiat Oncol Biol Phys. 2018;101(4):883-888.  https://doi.org/10.1016/j.ijrobp.2018.03.060
  7. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9—10 prostate cancer. JAMA. 2018;319(9):896-905.  https://doi.org/10.1001/jama.2018.0587
  8. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, Sandler H. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018;4(6):1-9.  https://doi.org/10.1001/jamaoncol.2018.0039
  9. Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, Aird EG, Bottomley D, Huddart RA, Jose CC, Matthews JH, Millar JL, Murphy C, Russell JM, Scrase CD, Parmar MK, Sydes MR. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464-473.  https://doi.org/10.1016/S1470-2045(14)70040-3
  10. Shahid N, Loblaw A, Chung HT, Cheung P, Szumacher E, Danjoux C, Sankreacha R, Zhang L, Deabreu A, Mamedov A, Morton G. Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer. Clin Oncol (R Coll Radiol). 2017;29(7):412-420.  https://doi.org/10.1016/j.clon.2017.01.042
  11. William RP, Zelefsky MJ. Improving outcomes in high-risk prostate cancer with radiotherapy. Rep Pract Oncol Radiother. 2013;18(6):333-337.  https://doi.org/10.1016/j.rpor.2013.10.006
  12. Morozov SP, Bezrukov EA. Tomographic methods in prostate cancer evaluation. Russian Electronic Journal of Radiology = Rossiiskii elektronnyi zhurnal luchevoi diagnostiki. 2011;1(4):18-26. (In Russ.).
  13. Roach M, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28(1):33-37.  https://doi.org/10.1016/0360-3016(94)90138-4
  14. NCCN Guidelines Version 2.2021. Prostate cancer, version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
  15. Murthy V, Maitre P, Bhatia J, Kannan S, Krishnatry R, Prakash G, Bakshi G, Pal M, Menon S. Mahantshetty U. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial. Radiother Oncol. 2020;145:71-80.  https://doi.org/10.1016/j.radonc.2019.12.006
  16. Deville C, Both S, Hwang WT, Tochner Z, Vapiwala N. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2020;78(3):763-772.  https://doi.org/10.1016/j.ijrobp.2009.08.043
  17. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48(3):635-642.  https://doi.org/10.1016/s0360-3016(00)00700-8
  18. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. J Clin Oncol. 2003;21(10):1904-1911. https://doi.org/10.1200/jco.2003.05.004
  19. Roach M 3rd, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR Jr, Shipley WU. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006; 66(3):647-653.  https://doi.org/10.1016/j.ijrobp.2006.05.074
  20. Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1504-1515. https://doi.org/10.1016/s1470-2045(18)30528-x

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.